p53 and γ radiation in the normal breast

References

• Andreassen CN, Alsner J, Overgaard J. 2002. Does variability in normal tissue reactions after radiotherapy have a genetic basis – where and how to look for it? Radiotherapy and Oncology 64:131–140.
   PubMed Web of Science ®Google Scholar
• Andreassen CN, Alsner J, Overgaard M, Overgaard J. 2003. Prediction of normal tissue radiosensitivity from polymorphism in candidate genes. Radiotherapy and Oncology 69:127–135.
   PubMed Web of Science ®Google Scholar
• Appella E, Anderson CW. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. European Journal of Biochemistry 268:2764–2772.
   PubMedGoogle Scholar
• Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pelegrin A. 2004. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Research 7:R156–R163.
   Google Scholar
• Badie C, Dziwura S, Raffy C, Tsigani T, Alsbeih G, Moody J, Finnon P, Levine E, Scott D, Bouffler S. 2008. Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment. British Journal of Cancer 98:1845–1851.
   PubMed Web of Science ®Google Scholar
• Barber JB, Burrill W, Spreadborough AR, et al 2000. Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer. Radiotherapy Oncology 55:179–186.
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Park C, Wright E. 2005. Radiation and the microenvironment – tumorigenesis and therapy. Nature Reviews Cancer 5:867–875.
   PubMed Web of Science ®Google Scholar
• Barwell J, Pangon L, Georgiou A, et al 2007. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. International Journal of Cancer 121:1631–1636.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Agrawal RK, Aird EG, et al 2008. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet 371:1098–1107.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. 1996. Radiotherapy-related lung fibrosis enhanced by tamoxifen. Journal of the National Cancer Institute 88:918–922.
   PubMedGoogle Scholar
• Blaydes JP, Craig AL, Wallace M, et al 2000. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene 19:3829–3839.
   PubMed Web of Science ®Google Scholar
• Brock WA, Tucker SL, Geara FB, et al 1995. Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer. International Journal of Radiation Oncology, Biology, Physics 32:1371–1379.
   PubMed Web of Science ®Google Scholar
• Burnet NG, Johansen J, Turesson I., Nyman J, Peacock JH. 1998. Describing patients' normal tissue reactions: Concerning the possibility of individualising radiotherapy dose prescriptions based on potential predictive assays of normal tissue radiosensitivity. International Journal of Cancer 79:606–613.
   PubMed Web of Science ®Google Scholar
• Burnet NG, Wurm R, Nyman J, Peacock JH. 1996. Normal tissue radiosensitivity – how important is it? Clinical Oncology 8:25–34.
   PubMedGoogle Scholar
• Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai, K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. 1998. Activation of the ATM kinase by ionising radiaiton and phosphorylation of p53. Science 281:1677–1679.
   PubMed Web of Science ®Google Scholar
• Castiglioni F, Terenziani M, Carcangui ML, Miliano R, Aiello P, Bertol L, Triulzi T, gasparini P, Camerini T, Sozzi G, Fossati-Bellani F, Menard S, Tagliabue E. 2007. Radiation effects on development of HER2-positive breast carcinomas. Clinical Cancer Research 13:46–51.
   PubMed Web of Science ®Google Scholar
• Chargari C, Toillon RA, MacDermed D, Castadot P, Magne N. 2009. Concurrent hormone and radiation therapy in patients with breast cancer: What is the rationale? Lancet Oncology 10:53–60.
   PubMedGoogle Scholar
• Coates PJ, Lorimore SA, Lindsay KJ, Wright EG. 2003. Tissue-specific p53 responses to ionizing radiation and their genetic modification: The key to tissue-specific tumour susceptibility? Journal of Pathology 201:377–388.
   PubMed Web of Science ®Google Scholar
• Coles CE, Moody AM, Wilson CB, Burnet NG, et al 2005. Reduction of radiotherapy-induced late complications in early breast cancer: The role of intensity-modulated radiation therapy and partial breast irradiation. Part I – normal tissue complications. Clinical Oncology (Royal College of Radiologists) 17:16–24.
   PubMed Web of Science ®Google Scholar
• Das S, Boswell SA, Aaronson SA, Lee SW. 2008. p53 promotor selection: Choosing between life and death. Cell Cycle 7:154–157.
   PubMed Web of Science ®Google Scholar
• Fachin AL, Mello SS, Sandrin-Garcia P, Junta CM, Donadi EA, Passos GAS, Sakamoto-Hojo ET. 2007. Gene expression profiles in human lymphocytes irradiated in vitro with low doses of gamma rays. Radiation Research 168:650–665.
   PubMed Web of Science ®Google Scholar
• Fei P, Bernhard EJ, El-Deiry WS. 2002. Tissue-specific induction of p53 targets in vivo. Cancer Research 62:7316–7327.
   PubMed Web of Science ®Google Scholar
• Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhoa H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett, Park M 2008. Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine 14:518–527.
   PubMed Web of Science ®Google Scholar
• Geara FB, Peters LJ, Ang KK, et al 1992. Intrinsic radiosensitivity of normal human fibroblasts and lymphocytes after high- and low-dose-rate irradiation. Cancer Research 52:6348–6352.
   PubMed Web of Science ®Google Scholar
• Gottlieb E, Haffner R, King A, et al 1997. Transgenic mouse model for studying the transcriptional activity of the p53 protein: Age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO Journal 16:1381–1390.
   PubMedGoogle Scholar
• Green DR, Chipuk JE (2006). p53 and metabolism: Inside the TIGAR. Cell 126:30–32.
   PubMed Web of Science ®Google Scholar
• Gurley KE, Kemp CJ. 2007. Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues. Molecular Cancer Research 5:1312–1318.
   PubMedGoogle Scholar
• Hiley C, Tutt A, Torres M, Palmieri C. 2009. Adjuvant radiotherapy for breast cancer. British Medical Journal 338:4–5.
   Google Scholar
• Huper G, Marks JR. 2007. Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. Cancer Research 67:2990–3001.
   PubMedGoogle Scholar
• Johansen J, Overgaard J, Overgaard M. 2007. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. Acta Oncologica 46:525–533.
   PubMed Web of Science ®Google Scholar
• Johansson S, Svensson H, Denekamp J. 2002. Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. International Journal of Radiation Oncology, Biology, Physics, 52:1207–1219.
   PubMed Web of Science ®Google Scholar
• Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Forance AJ. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597.
   PubMed Web of Science ®Google Scholar
• Komarova EA, Chernov MV, Franks R, et al 1997. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO Journal 16:1391–1400.
   PubMed Web of Science ®Google Scholar
• Komarova EA, Christov K, Faerman AI, Gudkov AV. 2000. Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene 19:3791–3798.
   PubMed Web of Science ®Google Scholar
• Lane DP. 1992. p53, guardian of the genome. Nature 358:15–16.
   PubMed Web of Science ®Google Scholar
• Lopez E, Guerrero R, Nunez MI, et al 2005. Early and late skin reactions to radiotherapy for breast cancer and their correlation with radiation-induced DNA damage in lymphocytes. Breast Cancer Research 7:R690–698.
   Web of Science ®Google Scholar
• López E, Núñez MI, Guerrero MR, Moral R, Luna JD, Rodríguez MM, Valenzuela MT, Villalobos M, Almodóvar JMR. 2002. Breast cancer acute radiotherapy morbidity evaluated by different scoring systems. Breast Cancer Research and Treatment 73:127–134.
   PubMed Web of Science ®Google Scholar
• MacCallum DE, Hupp TR, Midgley CA, et al 1996. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 13:2575–2587.
   PubMed Web of Science ®Google Scholar
• Midgley CA, Owens B, Briscoe CV, et al 1995. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. Journal of Cell Science 108:1843–1848.
   PubMed Web of Science ®Google Scholar
• Poeze M, von Meyenfeldt MF, Peterse JL, George WD, de Jong JMA, Jager JJ, Thunnissen FBJM 1998. Increased proliferative activity and p53 expression in normal glandular breast tissue after radiation therapy. Journal of Pathology 185:32–37.
   PubMedGoogle Scholar
• Renwick A, Thompson D, Seal S, et al 2006. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genetics 38:873–875.
   PubMed Web of Science ®Google Scholar
• Riches AC, Bryant PE, Steel CM, et al 2001. Chromosomal radiosensitivity in G2-phase lymphocytes identifies breast cancer patients with distinctive tumour characteristics. British Journal of Cancer 85:1157–1161.
   PubMed Web of Science ®Google Scholar
• Russel NS, Knaken H, Bruinvis IAD, Hart AAM, Begg AC, Lebesque JV. 1994. Quantification of patient to patient variation of skin erythema developing as a response to radiotherapy. Radiotherapy and Oncology, 30:213–221.
   PubMedGoogle Scholar
• Slonina D, Klimek M, Szpytma T, Gasinska A. 2000. Comparison of the radiosensitivity of normal-tissue cells with normal-tissue reactions after radiotherapy. International Journal of Radiation Biology, 76:1255–1264.
   PubMed Web of Science ®Google Scholar
• Song S, Lambert PF. 1999. Different responses of epidermal and hair follicular cells to radiation correlate with distinct patterns of p53 and p21 induction. American Journal of Pathology 155:1121–1127.
   PubMed Web of Science ®Google Scholar
• Staples O, Lain S, Ziyaie D, Thompson AM. p53 and breast cancer. In: Walker RA, Thompson AM, editors. Prognostic and predictive factors in breast cancer. London: Informa Healthcare, 2008. 148–167.
   Google Scholar
• Stebbing J, Delaney G, Thompson AM. Breast cancer (non-metastatic). Clinical evidence handbook. London: BMJ Publishing Group, 2008 pp. 606–609.
   Google Scholar
• Tan XL, Popanda O, Ambrosone CB, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J. 2006. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Research and Treatment 97:255–262.
   PubMedGoogle Scholar
• Turesson I., Nyman J., Holmberg E., Oden A. 1996. Prognosis factors for acute and late skin reactions in radiotherapy patients. International Journal of Radiation Oncology, Biology, Physics 36:1065–1076.
   PubMed Web of Science ®Google Scholar
• Vaidya JS, Baum M, Tobias JS, 14 others, Thompson A, Joseph D. 2006. Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost. International Journal of Radiation Oncology, Biology, Physics. 66:1335–1338.
   PubMedGoogle Scholar
• Vicini FA, Kestin L, Chen P, Benitez P, Goldstein NS, Martinez A. 2003. Limited-field radiation therapy in the mamnagement of early-stage breast cancer. Journal of the National Cancer Institute 95:1205–1210.
   PubMedGoogle Scholar
• Vousden KH, Lane DP. 2007. p53 in health and disease. Nature Reviews in Molecular and Cellular Biology 8:75–83.
   Google Scholar
• Wallace M, Coates PJ, Wright EG, Ball KL. 2001. Differential post-translational modification of the tumour suppressor proteins Rb and p53 modulate the rates of radiation-induced apoptosis in vivo. Oncogene 20:3597–3608.
   PubMed Web of Science ®Google Scholar
• Yap DB, Hsieh JK, Zhong S, et al 2004. Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Research 64:4749–4754.
   PubMedGoogle Scholar